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Stem cell researchers commonly use human pluripotent stem cell lines derived by other investigators.
Researchers may use lines derived elsewhere, provided that their derivation met consensus core standards.
Some types of derivation raise heightened levels of ethical concern and require greater scrutiny. To maintain
public trust, research institutions need to justify why they allow researchers to use lines whose derivation
would not have been permitted locally.Exchanginghumanpluripotentstemcell linesbetween institutions
across state and international borders will promote discovery,
confirmation, and future therapeutic applications in the emerging
field of stem cell research. Therefore, researchers may wish to
work with human stem cell lines that were derived at institutions
in other jurisdictions. Such sharing of materials also minimizes
the number of oocytes, embryos, and somatic cells used.
However, dilemmas arise because jurisdictions and institutions
may have conflicting standards on ethical issues; in some cases,
those lines might have been derived under conditions that would
not be permitted at the importing institution. Although it may not
be illegal for researchers to import and work on such lines, there
may be serious ethical concerns about undermining the home
jurisdiction’s ethical standards (Daley et al., 2007; Mathews
et al., 2006; Skene, 2007). For example, in 2007, the United
Kingdomdecided to allowwomen providing oocytes for research
to receive some payments for lost wages or discounts on their IVF
care (Human Fertilization and Embryology Authority, 2007). Using
such arrangements, UK researchers noware trying to derive a line
using somatic cell nuclear transfer (SCNT). If their efforts are
successful, other scientists will want to carry out additional
research with this line. However, under the National Academies
of Science (NAS) guidelines for human stemcell researchor under
laws in states such as California, donors of materials for stem cell
research may not receive payments or other consideration in
excess of out-of-pocket expenses (National Research Council
and Institute of Medicine, 2005). Therefore, institutions in the
United States will have to decide if their researchers can use lines
derived under such circumstances.It may be difficult to obtain accurate information about lines
derived in the past at other institutions. In several highly
publicized cases, key ethical facts were misrepresented or over-
looked. For example, clinical IVF programs in Romania lied about
payments to oocyte donors and were accused of exploiting
donors (Heng, 2006; Higgins, 2004). In the SCNT scandal in
Korea, in addition to fabricating data and committing financial
fraud, the principal investigator lied about payments to oocyte
donors, the recruitment of donors, and medical complication
rates (Chong, 2006; Chong and Normile, 2006; Normile et al.,
2006). Recently it has been alleged that problems with the
consent forms for several National Institutes of Health (NIH)-
approved embryonic stem cell lines went undetected for years
(Streiffer, 2008). This was partly a result of the lack of publicly
available documentation about the provenance of those lines,
which was not remedied until a Freedom of Information Act
request was filed with the NIH.
Institutions using human pluripotent stem cell lines derived at
another institution need to ensure that they were derived in an
ethically appropriate manner. The level of review should be
tailored to the level of ethical concern that the derivation proce-
dure raises. Human embryonic stem cell (hESC) lines derived
using fresh oocytes and embryos raise heightened concerns
about the medical risks of oocyte donation, undue influence,
compensation to oocyte donors, and compromise of the
reproductive goals of a woman in infertility treatment. However,
hESC lines derived from frozen embryos and induced pluripotent
stem (iPS) cell lines derived from somatic cells raise fewer ethical
concerns. Thus, review procedures for hESC lines derived usingCell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc. 115
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Perspectivefresh oocytes need to be more intensive than review procedures
for stem cell lines derived from frozen embryos or somatic cells.
Three questions need to be addressed regarding the use of
stem cell lines derived elsewhere. First, what ethical standards
for human pluripotent stem cell derivation should be required
everywhere in the world? Second, what review procedures are
needed to determine whether the derivation of a particular line
at another institution met these standards? Under what
conditions may an institution defer to review carried out in
a second institution? Third, under what circumstances may
researchers use human pluripotent stem cell lines whose deriva-
tion would not have been permitted in their own jurisdiction? For
instance, may a jurisdiction that does not allow oocyte donors to
receive payment greater than expenses allow researchers to
import stem cell lines derived from fresh oocytes whose donors
received such payments?
What Research Ethics Standards Should Apply
in All Countries?
Donation of biological materials for the derivation of human
pluripotent stem cell lines should meet core ethical standards
in consensus international research guidelines. First, the risks
to research participants, such as oocyte donors, must be
minimized and reasonable in light of the prospective benefits.
Second, informed and voluntary consent must be obtained as
a matter of respect for donors. Payment should not present an
undue inducement to donors. As a procedural safeguard, the
derivation should have been approved by an institutional review
board (IRB) or similar oversight panel that is independent of the
investigators. These ethical standards are identified as funda-
mental in international standards such as the Helsinki Declara-
tion, the Council for International Organizations of Medical
Sciences (CIOMS), and International Ethical Guidelines for
Biomedical Research Involving Human Subjects, Good Clinical
Practice (GCP) standards; in United States regulations for the
protection of human subjects (Council for International Organiza-
tions of Medical Sciences, 2002; Department of Health and
Human Services, 2005; International Conference on Harmoniza-
tion, 2007; U.S. Food and Drug Administration, 2007; World
Medical Association); and in stem cell-specific standards from
the International Society for Stem Cell Research (ISSCR), the
U.S. National Academy of Sciences, the California Institute for
Regenerative Medicine, and others (California Institute for
Regenerative Medicine, 2006; International Society for Stem
Cell Research, 2006; National Academy of Sciences, 2005;
National Institutes of Health, 1994; Streiffer, 2008).
If These Consensus Guidelines Were Violated,
May Other Researchers Still Use the Derived
Stem Cell Lines?
On the one hand, using such previously derived human stem cell
lines allows some good to come from the risks and inconve-
nience that the donors of research materials experienced. There
are no further physical risks to donors. However, such use would
fail to respect as persons those donors whose consent was not
sought, who were not informed of the proposed type of research
activity, or who would have objected to it. There might also
be violations of privacy and confidentiality if the lines are
identifiable. Furthermore, such use may erode ethical behavior
by other researchers. If some stem cell researchers were116 Cell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc.permitted to take advantage of lax standards or weak oversight
in certain jurisdictions, other investigators throughout the world
would be at a considerable disadvantage in a highly competitive
field. They therefore would have strong incentives to reject these
consensus standards. Eventually the most permissive practices
might prevail. In a global research environment, stem cell
research may move to countries that lack ‘‘restrictive policies’’
(Brown, 2007). These slippery-slope concerns are cogent
because it would be difficult to set a policy that allows use of
one human stem cell line that was derived in an unethical manner
while preventing the sharing of additional such lines in the future.
In addition, use of such lines may be problematic per se. Philos-
ophers have debated whether it is wrong for one person to ‘‘take
up and incorporate fruits or byproducts of someone else’s illicit
action’’ in order to carry out an essential part of one’s own
project (Kaveny, 2000).
What Obligations Do Researchers and Institutions Using
Stem Cell Lines Derived Elsewhere Have to Verify
that Consensus Standards Have Been Met?
A scientist may not avoid moral responsibility by claiming that
she had no control over collaborators’ actions or that she did
not know what they did. In cases of egregious scientific miscon-
duct, scientists have been criticized even though they claimed
that they were not aware that collaborators had falsified or
fabricated data (Culliton, 1983; Holden, 2006; Rennie, 2008).
While researchers cannot be expected to know all the details
of a collaborator’s work, they need to be satisfied that consensus
core ethical standards were met. Although trusting collaborators
is an honored scientific tradition, it would be naive to simply rely
on a colleague’s word that the stem cell line was derived
ethically. Researchers importing human stem cell lines and their
institutions need to make reasonable efforts to verify that a line
was derived in an ethical manner. Requiring documentation is
one such necessary step in assessing whether consensus
ethical standardsweremet, although it would not protect against
intentional deception. What kinds of evidence, however, should
an institution require to determine that the derivation met
consensus ethical standards? At the University of California,
San Francisco (UCSF), the Stem Cell Research Oversight
Committee (SCRO) has decided that the level of review must
be proportionate to the level of ethical concerns about the
method of derivation.
The next sections suggest how SCROs and researchers
should take into account a number of considerations when
deciding whether it is permissible to use a line derived in another
jurisdiction.
Review of Human Pluripotent Stem Cell Lines that Raise
Relatively Low Levels of Ethical Concern
Stem Cell Lines Derived from Frozen Embryos
Remaining after Completion of IVF Treatment
Figure 1 presents recommendations for such lines derived from
embryos created for reproductive purposes before April 2005,
when the National Academy of Sciences (NAS) recommended
ethical standards for hESC research. Lines derived after this
date will be considered in the next section.
Legal Compliance. At a minimum, the derivation should have
complied with all applicable legal and clinical standards for
in vitro fertilization (IVF) in that jurisdiction at that time.
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Figure 1. When May an Investigator Use an hESC Line Derived at Another Institution from a Frozen Embryo Created before April 2005 for
Reproductive Purposes?
Yellow boxes and arrows allow consideration of exceptions on a case-by-case basis. See text for details.
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embryos remaining after a woman or couple has completed
infertility treatment, the main ethical concerns are informed
consent for stem cell research and payment to the embryo or
gamete donors. There is no additional physical risk to oocyte
donors, who have already experienced the risks of hormonal
manipulation and oocyte retrieval in order to achieve reproduc-
tive goals. The ethical concern is that a person who donated
gametes or embryos for research purposes may not want those
materials used for hESC research or was not asked for consent
(Lo et al., 2003). Explicit and voluntary consent for use of repro-
ductive materials in hESC or SCNT research should ideally have
been obtained from any gamete donors as well as embryo
donors (National Academy of Sciences, 2005).
Payment. Any payment to a gamete donor(s) that was
provided previously in the context of infertility treatment should
comply with prevailing clinical standards in IVF practices. The
use of frozen embryos for research provides no additional
inducement to gamete donors because at the time of donation
all gametes were intended for use in infertility treatment.
To avoid undue inducement with embryo donors, there should
be no payment for frozen embryos beyond reimbursement forreasonable and actual expenses for documenting consent and
shipping materials. There is no rationale for paying embryo
donors for materials that have already been obtained as part of
clinical care but are no longer needed for that purpose, just as
patients are not paid for research use of pathological specimens
obtained during clinical care.
Exceptional Cases. An exception may be made to ‘‘grand-
parent’’ in older lines that were derived from embryos created
before explicit consent for hESC derivation became the standard
of care (Sugarman and Siegel, 2008a, 2008b). A 1994 NIH panel
on human embryo research recommended that consent from
embryo and gamete donors be required; however, that report
was never officially adopted. Subsequent guidelines and articles
also called for various aspects of informed consent for hESC
derivation (Lo et al., 2003; National Bioethics Advisory Commis-
sion, 1999; Streiffer, 2008). Although these recommendations
are ethical best practices, it is controversial whether they should
be considered a requirement for researchers. However, the April
2005 National Academies’ Guidelines for Human Embryonic
Stem Cell Research may be regarded as definitive because it
is a consensus, peer-reviewed report and has been widely
adopted as institutional policy and state regulation (LomaxCell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc. 117
Derivation complied with all 
applicable legal and clinical 
standards for IVF in that 
jurisdiction
YES
Gamete donor(s) gave 
voluntary and informed 
consent specifically for 
hESC derivation
The embyro used was 
created from donor gametes
Any payment to embryo donors was 
only for reasonable and actual 
expenses for documenting consent 
and shipping materials
Investigator may use 
line in proposed 
research
Line may be 
approved on a 
case-by-case
basis
Investigator
may not use line 
in proposed 
research
Any payment to oocyte 
donor complied with 
prevailing clinical
standards in IVF at the 
time
There are 
compelling
scientific reasons 
for using the 
specific line
Gamete donors 
gave consent for 
general research 
or granted rights
of disposition to 
IVF couple 
NO
NO
NO
NO
NO NO
NO YES
YES
YES
YES
YES
YES
Embryo donor(s) gave 
informed and voluntary 
consent  specifically for hESC 
derivation
YES
NO
Figure 2. When May an Investigator Use an hESC Line Derived at Another Institution from a Frozen Embryo Created after April 2005 for
Reproductive Purposes?
Blue text indicates different standards from those presented in Figure 1. Yellow boxes and arrows allow consideration of exceptions on a case-by-case basis.
Please see text for explanation.
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situations for researchers to use hESC lines derived before April
2005 from donors who did not provide explicit consent. The first
situation is that in which consent was obtained for research, but
not specifically for stem cell research, and the proposed project
is consistent with that consent. The second situation is that in
which a gamete donor granted rights of disposition to thewoman
or couple in IVF treatment and there is a strong scientific reason
to use the particular line. A ‘‘strong’’ scientific reason for using
the derived hESC line would be that it has unique immunological
properties that would be advantageous in transplantation or that
it is the only line that has been differentiated into a specialized
type of cell. Looking at Figure 1, the SCRO would follow the
dotted yellow arrows to make a determination on a case-by-
case basis as to whether a particular line may be used.
For lines derived from embryos created after the April 2005
NAS recommendations, there should be higher standards for
consent from embryo and gamete donors, as the text highlighted
in blue in Figure 2 describes. The yellow boxes and dashes show
the path for consideration of exceptions. A ‘‘compelling’’ scien-118 Cell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc.tific reason should be required to use a line that does not meet
the NAS consent standards, not just a ‘‘strong’’ reason. In our
view, a line that is the only suitable one derived under Good
Manufacturing Practice for clinical use would qualify, because
the effort and expense of repeating the derivation might well
be prohibitive. The scientific benefits, which are substantial,
are therefore unlikely to be duplicated in other lines. When
making a determination that there is a compelling scientific
reason, the SCRO committee should state its justification
explicitly.
Process of Review. We recommend that for hESC lines
derived from frozen embryos, a researcher or research institution
may rely on the review process carried out in another country or
institution, provided the following four criteria are met. First,
the policy in which the hESC line was derived incorporates the
consensus core standards discussed above. Second, the
donation of embryos for research met the ethical, legal, and
institutional standards in place at the time. Third, a panel with
appropriate expertise and experience approved the consent
and derivation processes and carried out review appropriately.
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exceed explicit provisions in the consent for donation of
embryos to researchers (Streiffer, 2008).
In our experience at UCSF, it is difficult and time consuming to
obtain such information. Many institutions do not have informa-
tion about the review committee and process readily available
and are not used to responding to such requests. Even obtaining
the qualifications and experience of the review panel may be
challenging. It may be particularly difficult to obtain information
about hESC lines derived by for-profit companies that were
bought out by another company.
In light of the relatively low level of risk in deriving hESC lines
from frozen embryos, the UCSF SCRO decided that extensive
time and effort for detailed verification is not warranted.
Thus, for such lines, UCSF has decided to rely on a letter
signed by a responsible official from the institution where the
line was derived stating that the derivation from frozen embryos
was approved by the appropriate institutional committee, that
the institution has adopted consensus core ethical guidelines
(for example, the 2005 NAS guidelines or the 2007 ISSCR guide-
lines), and that the protocol met legal requirements in force at the
time of derivation. In addition, in light of recent concerns about
donor consent (Streiffer, 2008), the UCSF SCRO also reviews
the consent form for the donation of embryos used for the
derivation of stem cell lines.
To facilitate sharing of stem cell lines, institutions at which
widely used lines were derived should post on the Internet docu-
mentation that SCROs at other institutions need to determine if
they approve the use of the lines. Such information should
include documentation of institutional approval, unsigned copies
of consent forms, and a description of the process by which
consent and materials were obtained.
Derived Lines. If a researcher proposes to use a secondary
stem cell line derived from a hESC line for which the embryo or
gamete donors did not explicitly consent for hESC research—
for example, a committed cell line derived from a pluripotent
cell line—the same standards and review process should apply.
If the original cell line is determined to be acceptable according
to the standards and procedures discussed above, then the
derivative line should also be acceptable.
Induced Pluripotent Stem Cell Lines
Derivation of iPS Cell Lines. When deriving iPS cell lines, the main
ethical concern is informed consent from the somatic cell donor.
Preferably, consent should be obtained specifically to create
human pluripotent stem cell lines. Consent, however, for unspec-
ified future researchsuffices toderive the line, showthat it isplurip-
otent, and carry out other basic research that is commonly carried
out with other cells under such general consent. A researcher also
may use deidentified cells donated for another purpose, provided
that theuseof thecells toderivean iPScell linedoesnot contradict
the provisions of consent for the original donation.
In the case of iPS, payment to somatic cell donors is not as
great a concern as with gamete or embryo donors. Donating
somatic cells is not as ethically sensitive as donating reproduc-
tive cells, and donors commonly receive a small payment
when undergoing biopsies in other types of research without
raising concerns about undue influence. The review process
for iPS cell lines should be the same as for hESC lines derived
from frozen embryos remaining after IVF treatment.Human Stem Cell Lines that Raise Higher Levels
of Ethical Concern
Some methods of deriving human pluripotent stem cell lines
raise higher levels of ethical concern. Our analysis goes beyond
previous discussions of sharing stem cell lines derived in another
jurisdictions by suggesting more specific guidelines and proce-
dures to assist oversight committees who must approve such
sharing (Beauchamp and Childress, 2001; Daley et al., 2007;
Mathews et al., 2006; Skene, 2007).
hESC Lines Derived Using Fresh Oocytes
or Fresh Embryos
Such lines raise additional concerns about medical risk and, if
materials are shared between researchers and a woman in
infertility treatment, concerns about compromising reproduc-
tive goals (see Figure 3) (Cohen et al., 2008; Lomax et al.,
2007).
Legal Compliance. At a minimum, the derivation should
comply with all applicable legal and clinical standards for IVF in
that jurisdiction.
Consent. When stem cell lines are derived by using fresh
oocytes or fresh embryos, there are ethical concerns about
consent and medical risks to donors. Consent for donation of
such materials for research should be specific, informed, and
voluntary. If any gamete or embryo donors had low education,
lived in poverty, or had dependent relationships with investiga-
tors, it should be explained how it was determined that their
consent was both informed and voluntary.
Exception for Compelling Scientific Reasons. A hESC line that
does not meet these consent requirements may be granted an
exception to be used. For example, a hESC line that was derived
from fresh oocytes or embryos obtained before April 2005 may
not meet the NAS standards for specific consent for hESC
derivation. The SCRO may determine on a case-by-case basis
that compelling scientific reasons to use the line outweigh ethical
concerns about consent. For example, in a case in which a
gamete donor(s) granted dispositional control to an IVF couple,
a compelling scientific reason to grandfather the line might be
that it was derived under Good Manufacturing Practice for
clinical use.
Medical Risks. In research, risks to participants must be
minimized. The concern here is that attempts may be made
to retrieve a larger-than-usual number of oocytes. The risk of
ovarian hyperstimulation syndrome (OHSS) is increased if
a large number of oocytes is sought (Giudice et al., 2007).
The most direct method to assess risk is to compare the
incidence of severe OHSS in the women who donated oocytes
for research to the incidence at experienced, skilled IVF centers
with comparable donors. However, the number of cases will be
small, and the confidence intervals around the rates will be
wide. In addition, there should be documentation of procedures
designed to minimize risks to donors, such as excluding donors
at high risk for complications, using appropriate hormonal
dosage, aiming for a modest number of oocytes, monitoring
for excessive ovarian stimulation, and canceling an induction
cycle when the risk of OHSS is unacceptable (Balen, 2005;
Giudice et al., 2007).
Oocyte Sharing. There are additional ethical concerns if
oocytes from a donor cycle were used for both reproductive
purposes and for research. For example, fresh oocytes mightCell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc. 119
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Figure 3. When May an Investigator Use
hESC Lines Derived at Another Institution
from Fresh Oocytes or Fresh Embryos?
Cell Stem Cell
Perspectivebe shared between a woman in IVF treatment and researchers,
or researchers might receive oocytes that failed to fertilize or
that were too immature for reproductive use. There is no addi-
tional medical risk to oocyte providers who are already under-
going oocyte retrieval for reproductive purposes, provided that
hormonal dosing protocols are not intensified. However, oocyte
sharing might compromise reproductive outcomes for the
woman in infertility treatment, particularly when oocytes other
than those that are immature or fail to fertilize are shared. In
this setting, the reproductive success and interests of the
woman in infertility treatment should not be compromised.
Direct evidence that the woman in infertility treatment did not
have her reproductive interests compromised would be that
reproductive outcomes in women who shared oocytes with
researchers were similar to outcomes in women at the IVF clinic
who had all oocytes available for use in reproduction (Revazova
et al., 2007). Supporting evidence that reproductive outcomes
were not compromised can be obtained from the safeguards in
the donation protocol.120 Cell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc.If researchers receive oocytes that
failed to fertilize or fresh embryos that
are not of reproductive quality, there are
again concerns about compromising the
reproductive goals of the woman in infer-
tility treatment. The embryologist who
decides that these materials are not suit-
able for reproductive purposes should be
independent of the research team, be
blinded as to whether such materials
would be discarded or used for research,
and have no financial interest in compa-
nies with a financial stake in human
stem cell research (California Institute
for Regenerative Medicine, 2006; Lomax
et al., 2007).
Some women who could not otherwise
afford IVF might be willing to accept
a lower pregnancy rate in order to obtain
subsidized or free IVF cycles by providing
oocytes for research. This determination
must be an informed decision made by
the woman undergoing treatment (Cali-
fornia Institute for RegenerativeMedicine,
2006).
Payment or Consideration to
Oocyte Donors in Excess
of Expenses
Jurisdictions have conflicting policies
about payment to oocyte donors. Reim-
bursement to oocyte donors for out-of-
pocket expenses presents no ethical
problems, because donors gain no finan-
cial advantage from participating inresearch. However, payment to oocyte donors in excess of
reasonable out-of-pocket expenses is controversial, and juris-
dictions have different policies (Spar, 2007). Good arguments
can be made both for and against paying donors of research
oocytes more than just their expenses (Hyun, 2006).
Jurisdictions and institutions that forbid such payments need
to decide whether researchers may use human stem cell lines
derived elsewhere using embryos whose oocyte donors were
paid. Several considerations should be taken into account.
First, what kind of policy in the other jurisdiction allowed
payment? Some policies have a strong claim to be respected
elsewhere because they represent the values and culture of that
jurisdiction and were carefully considered. For example, the UK
enacted an explicit policy to allow such payment after public
consultation and debate and careful deliberation and provided
reasons to justify its decision (Human Fertilisation and Embry-
ology Authority, 2006, 2007a, 2007b, 2007c). These reasons are
understandable to persons from different religious or philosoph-
ical traditions (National Bioethics Advisory Commission, 1997).
Table 1. Information to Disclose to Donors Regarding Future
Research
1. Genetic modifications of cells.
2. Injection of derived cells into nonhuman animals to demonstrate
their function or safety, including the injection into the brains of
nonhuman animals.
3. Large-scale genome sequencing.
4. Future research projects that cannot be anticipated currently.
5. Sharing cell lines with other researchers in other institutions and
countries, with confidentiality protections.
6. Patenting scientific discoveries and developing commercial tests
and therapies, with no sharing of royalties with donors.
7. Allogenic transplantation.
8. Reproductive research to create totipotent entities from gametes
derived from pluripotent stem cells.
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carefully considered policies as embodying a reasonable differ-
ence of opinion on a complex issue. In contrast, some jurisdic-
tions have no explicit policy regarding such payments. Thus
payments are permitted simply because they are not forbidden,
which may be a loophole rather than a deliberate policy. Such
an approach has only weak claims to be accepted by other juris-
dictions. Public policies are more deserving of respect if they
are explicit, justified by reasons, and involve public deliberation
(Gutman and Thompson, 1996).
Second, was the payment or consideration an undue influ-
ence? An undue inducement or undue influence is defined as
‘‘an offer of an excessive, unwarranted, inappropriate or
improper reward or other overture in order to obtain compliance’’
(National Commission for the Protection of Human Subjects of
Biomedical andBehavioral Research, 1979). Very high payments
to participants might be regarded as an undue influence,
because they might lead persons to agree to inappropriately
large risks they would otherwise not accept. The amount paid
to participants should be specified, as well as how it compares
with such benchmarks as typical hourly incomes for unskilled
labor, the minimum wage, and the cost of living in that area.
The review committee of the institution at which the line was
derived should explain the reasons that led them to determine
there was no undue influence. For instance, the researchers
might have administered a questionnaire to ensure that donors
appreciated the medical risks and any potential impact on
reproductive outcomes. In addition, there might have been
a waiting period to allow oocyte providers to reconsider their
decision.
Other Sensitive Methods for Deriving Pluripotent Lines
Some approaches to deriving pluripotent stem cells, such as
SCNT or use of nonhuman oocytes in SCNT, raise additional
ethical controversies regarding natural ethical boundaries and
human dignity (Human Fertilisation and Embryology Authority,
2007d; National Bioethics Advisory Commission, 1997; The
President’s Council on Bioethics, 2002). These techniques are
not permitted in some jurisdictions. The issue is whether
a different policy in the other jurisdiction has a strong claim to
be respected because it was carefully deliberated on and
justified, as discussed previously (Human Fertilisation and
Embryology Authority, 2007d). In such instances, the donors ofmaterials should have given consent for these specific tech-
niques, rather than just general consent for ‘‘research’’ or
‘‘stem cell derivation.’’ The researcher who wants to import the
lines should explain why the project could not be carried out
by other, less ethically sensitive methods, such as by using iPS
cells.
Sensitive Downstream Stem Cell Research
Some types of downstream research with stem cells raise higher
levels of ethical concern. Human allogenic transplantation and
reproductive research to create a totipotent entity using gametes
derived from pluripotent stem cells are likely to be particularly
controversial; a significant percentage of donors of materials
used to derive stem cells can be predicted to disapprove of
them, and explicit consent is generally required for these activi-
ties in other settings (Aalto-Setala et al., 2009).
Researchers would fail to respect donors as persons if donors
were not informed of the proposed type of research, or if donors
would have objected to it (Aalto-Setala et al., 2009). Thus these
types of sensitive downstream research should be permitted
only if donors explicitly consented to them (Aalto-Setala et al.,
2009).
Given the barriers to future research if the donor has not given
consent, researchers deriving a new stem cell line can facilitate
downstream research if they inform donors of the types of
research that might be carried out in the future, as shown in
Table 1. Donors should be given the option of consenting to
only some of these research activities. However, we suggest
that researchers use only materials from donors who agree to
items 1–6 in Table 1, which are fundamental in basic and
translational stem cell research whose goal is new therapies. If
donors allowed only some of these activities, the scientific
usefulness of the lines would be compromised; they could not
be characterized fully, studied extensively, or differentiated into
specialized cells.
Procedures for Review of Human Stem Cell Lines
that Raise Higher Levels of Ethical Concern
Such human pluripotent stem cell lines might be approved
through various review procedures, depending on the circum-
stances of the case.
Accept Original Review of Derivation. Review of the derivation
by another institution may be accepted if certain criteria are met.
First, the policy in the jurisdiction should incorporate core
consensus ethical principles, should be explicit and accompa-
nied by a rationale that is publicly available and understandable
to persons from different religious and philosophical traditions,
and should address concerns about undue influence.
Second, the original review of the derivation protocol should
have been careful and rigorous. This might occur in several
ways. Review by national bodies, such as those in the UK and
Canada, and Australia (Canadian Institutes of Health Research,
2007; Human Fertilization and Embryology Authority, 2003;
National Health and Medical Research Council, 2004), are likely
to be equivalent to, if not superior to, oversight at importing
institutions and therefore need not be duplicated. It is important,
however, to note that uncritical reliance on original review by
national bodies might be problematic; the NIH, for example,
seems to have conducted little substantive review of the prove-
nance for the hESC lines on its registry (Streiffer, 2008), relying
instead on statements from the providers. Additionally, theCell Stem Cell 4, February 6, 2009 ª2009 Elsevier Inc. 121
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PerspectiveNAS deferred to the NIH in their decision to grandfather those
lines into their 2007 guidelines.
Indirect assessments of another institution’s review process
might be problematic. SCROs are not accredited, so it is difficult
to judge their expertise and procedures. A statement from the
deriving institution’s SCRO stating that it is in compliance with
the latest NAS or ISSCR guidelines would strengthen an indirect
assessment of that SCRO. If the SCRO is not fully in compliance
with the NAS or ISSCR guidelines, a document showing how the
SCRO’s review process differs would also be helpful. Addition-
ally, review bodies at other institutions might be deemed accept-
able if the IRB for human subjects research has been accredited.
Although human subjects review and stem cell research review
are different, accreditation indicates an institutional commitment
to rigorous review of research.
Review of Derivation by Institution Importing the Stem Cell
Line. If the review process of the institution at which the stem
cell line was derived does not satisfy these criteria, the institution
where the line would be used will have to review the derivation
protocol after the fact. The most direct way to do so is for the
original review panel to share its reasoning with the SCRO of
the institution at which the line would be used—for example, in
detailed minutes or in a peer-reviewed publication. The latter
committee can then judge whether it regards the review as thor-
ough and the reasoning as persuasive. At UCSF, we have found
such case-by-case reviews, which might need to assess
informed consent processes in another country, to be highly
labor intensive and often impractical. Because of these difficul-
ties, we strongly prefer to obtain enough information to defer
to the original review, as discussed previously.
Separation of Scientist Importing Stem Cell Line from Deriva-
tion. If a researcher uses an imported hSC line whose derivation
would not have been permitted where she works, she should not
instigate, direct, or coordinate the derivation of stem cell lines
in the institution of origin. Otherwise, the collaboration could
be considered a subterfuge to evade restrictions at the home
institution.
In summary, stem cell lines may be shared across jurisdic-
tions, provided that the derivation was carried out in accordance
with consensus core ethical standards and that there is
adequate evidence that these standards were met. Institutions
need to be willing to explain to the public how they are over-
seeing human stem cell research andwhy they allow researchers
to use a line whose derivation would not have been permitted
there. In a new and sensitive field of research, such justification
is essential to strengthen public trust.
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